According to filings with the U.S. Securities and Exchange Commission, AOA DX Inc. is raising up to $30,582,903.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About AOA DX Inc.
AOA Dx is leading a revolutionary breakthrough in early-stage cancer detection for women, leveraging the transformative potential of AI and our proprietary biomarker technology. At the heart of this innovation is our GlycoLocate platform, a multi-omics approach powered by tumor marker gangliosides, lipids and proteins. This platform is setting a new gold standard in the quest for life-saving early cancer diagnostics. We are now advancing AKRIVIS GD, a cutting-edge liquid biopsy test designed specifically for the early detection of ovarian cancer.

To learn more about AOA DX Inc., visit https://aoadx.com/
AOA DX Inc. Linkedin Page: https://www.linkedin.com/company/aoadx/

Contact:
Oriana Papin-Zoghbi, President
617-903-0350
https://www.linkedin.com/in/orianazh/

SOURCE: http://www.intelligence360.io
Copyright (c) 2025 SI360 Inc. All rights reserved.